These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37634194)

  • 1. Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals.
    Fritch EJ; Mordant AL; Gilbert TSK; Wells CI; Yang X; Barker NK; Madden EA; Dinnon KH; Hou YJ; Tse LV; Castillo IN; Sims AC; Moorman NJ; Lakshmanane P; Willson TM; Herring LE; Graves LM; Baric RS
    J Proteome Res; 2023 Oct; 22(10):3159-3177. PubMed ID: 37634194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.
    Kindrachuk J; Ork B; Hart BJ; Mazur S; Holbrook MR; Frieman MB; Traynor D; Johnson RF; Dyall J; Kuhn JH; Olinger GG; Hensley LE; Jahrling PB
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1088-99. PubMed ID: 25487801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
    Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.
    Garcia G; Sharma A; Ramaiah A; Sen C; Purkayastha A; Kohn DB; Parcells MS; Beck S; Kim H; Bakowski MA; Kirkpatrick MG; Riva L; Wolff KC; Han B; Yuen C; Ulmert D; Purbey PK; Scumpia P; Beutler N; Rogers TF; Chatterjee AK; Gabriel G; Bartenschlager R; Gomperts B; Svendsen CN; Betz UAK; Damoiseaux RD; Arumugaswami V
    Cell Rep; 2021 Apr; 35(1):108940. PubMed ID: 33784499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins.
    de Wilde AH; Wannee KF; Scholte FE; Goeman JJ; Ten Dijke P; Snijder EJ; Kikkert M; van Hemert MJ
    J Virol; 2015 Aug; 89(16):8318-33. PubMed ID: 26041291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target.
    Li C; Chu H; Liu X; Chiu MC; Zhao X; Wang D; Wei Y; Hou Y; Shuai H; Cai J; Chan JF; Zhou J; Yuen KY
    Emerg Microbes Infect; 2020 Dec; 9(1):2663-2672. PubMed ID: 33179566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy.
    Fattahi S; Khalifehzadeh-Esfahani Z; Mohammad-Rezaei M; Mafi S; Jafarinia M
    Immunol Res; 2022 Jun; 70(3):269-275. PubMed ID: 35107743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
    Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
    J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection.
    Comar CE; Goldstein SA; Li Y; Yount B; Baric RS; Weiss SR
    mBio; 2019 Mar; 10(2):. PubMed ID: 30914508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
    de Wilde AH; Jochmans D; Posthuma CC; Zevenhoven-Dobbe JC; van Nieuwkoop S; Bestebroer TM; van den Hoogen BG; Neyts J; Snijder EJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4875-84. PubMed ID: 24841269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses.
    Ahn DG; Yoon GY; Lee S; Ku KB; Kim C; Kim KD; Kwon YC; Kim GW; Kim BT; Kim SJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery.
    Kandeel M
    Expert Opin Drug Discov; 2023 Apr; 18(4):385-400. PubMed ID: 36971501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.